Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
IL-3 promotes the development of experimental autoimmune encephalitis
Kerstin Renner, Sonja Hellerbrand, Fabian Hermann, Christine Riedhammer, Yvonne Talke, Gabriela Schiechl, Manuel Rodriguez Gomez, Simone Kutzi, Dagmar Halbritter, Nicole Goebel, Hilke Brühl, Robert Weissert, Matthias Mack
Kerstin Renner, Sonja Hellerbrand, Fabian Hermann, Christine Riedhammer, Yvonne Talke, Gabriela Schiechl, Manuel Rodriguez Gomez, Simone Kutzi, Dagmar Halbritter, Nicole Goebel, Hilke Brühl, Robert Weissert, Matthias Mack
View: Text | PDF
Research Article

IL-3 promotes the development of experimental autoimmune encephalitis

  • Text
  • PDF
Abstract

Little is known about the role of IL-3 in multiple sclerosis (MS) in humans and in experimental autoimmune encephalomyelitis (EAE). Using myelin oligodendrocyte glycoprotein (MOG) peptide–induced EAE, we show that CD4+ T cells are the main source of IL-3 and that cerebral IL-3 expression correlates with the influx of T cells into the brain. Blockade of IL-3 with monoclonal antibodies, analysis of IL-3 deficient mice, and adoptive transfer of leukocytes demonstrate that IL-3 plays an important role for development of clinical symptoms of EAE, for migration of leukocytes into the brain, and for cerebral expression of adhesion molecules and chemokines. In contrast, injection of recombinant IL-3 exacerbates EAE symptoms and cerebral inflammation. In patients with relapsing-remitting MS (RRMS), IL-3 expression by T cells is markedly upregulated during episodes of relapse. Our data indicate that IL-3 plays an important role in EAE and may represent a new target for treatment of MS.

Authors

Kerstin Renner, Sonja Hellerbrand, Fabian Hermann, Christine Riedhammer, Yvonne Talke, Gabriela Schiechl, Manuel Rodriguez Gomez, Simone Kutzi, Dagmar Halbritter, Nicole Goebel, Hilke Brühl, Robert Weissert, Matthias Mack

×

Figure 2

Blockade of IL-3 reduces development of EAE.

Options: View larger image (or click on image) Download as PowerPoint
Blockade of IL-3 reduces development of EAE.
EAE was induced in C57BL/6 ...
EAE was induced in C57BL/6 mice by immunization with MOG peptide 35-55 on day 0. From day 0–19, mice were treated with an intact or deglycosylated neutralizing anti–IL-3 antibody (anti–IL-3, 50 μg/day) or purified rat IgG (Control, 50 μg/day) (n = 14-15/group). (A and C) Clinical symptoms of EAE (EAE score) were significantly ameliorated (P < 0.01) in anti–IL-3–treated mice. (B and D) Leukocytes infiltrating the brain were quantified by flow cytometry on day 20. Monocytes (Monos) and total leukocytes (CD45+) were reduced by blockade of IL-3, while infiltrating CD4+ T cells, CD8+ T cells, and CD19+ B cells were not different between the groups. (E) On day 20, splenocytes were restimulated with MOG peptide 35-55 or PBS as control for 3 days, and the levels of IFN-γ, IL-6, and IL-17 were measured in the supernatant by ELISA. One out of 2 representative experiments is shown. Data are represented as mean ±SEM, Student’s t test of control vs. anti–IL-3: *P ≤ 0.05, **P < 0.01, ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts